1 report

  • 03/09/2016: Probiodrug PGLU-ABETA Approaches Being Presented At 14Th Aat Symposium On Advances In Alzheimer Therapy
  • Apr 04, 2016: Probiodrug announces results of chronic toxicology studies with PQ912, its 'first in class' Glutaminyl Cyclase inhibitor for the treatment of Alzheimer's disease

They have a remaining term of up to one year.

  • Dementia
  • Healthcare
  • Pathology
  • United States
  • Probiodrug AG